Skip to main content
. 2023 May 23;14:1104890. doi: 10.3389/fimmu.2023.1104890

Figure 7.

Figure 7

In vivo effects of the miR-503/IGF1R axis on diabetic mice wound healing (A) Mouse skin wound model was established in control or streptozotocin (STZ)-induced diabetic mice and divided into six groups: control, DM+sEVs, DM+inhibitor NC DM+sEVs + sh-NC, DM+miR-503 inhibitor sEVs + sh-NC, DM+inhibitor NC sEVs + sh-IGF1R, and DM+miR-503 inhibitor sEVs + sh-IGF1R. Mice in each group were treated accordingly. (B) The appearance of the wound on days 0, 3, 6, and 12 was shown. (C) Wound closure on day 0, 3, 6, and 12 was calculated. n=8. (D) The blood glucose were determined at day 12. n=8. (E-G) On day 12, mice were sacrificed, skin samples were collected, and the expression of miR-503, IGF1R, IL-1β, TNF-α, and iNOS were examined; the protein levels of iNOS, CD163, and IGF1R were examined using Immunoblotting (G). n=3. ** p<0.01 vs. control group. aa p<0.01 vs. DM+inhibitor NC-sEVs+sh-NC group. bb p<0.01 vs. DM+miR-503 inhibitor -sEVs+sh-IGF1R group. * p<0.05. p<0.01 vs. control group. a p<0.05, aa p<0.01 vs. DM+inhibitor NC-sEVs+sh-NC group. b p<0.05, bb p<0.01 vs. DM+miR-503 inhibitor -sEVs+sh-IGF1R group.